attomarker

The Vision

The Challenge

For centuries, doctors have relied on symptoms to diagnose illnesses, but with over 4,000 diseases and under 400 symptom terms*, misdiagnosis and delayed treatment are common. Laboratory tests have helped, but results often take too long to reach clinicians—by which time treatment decisions may have already been made.Speed matters. In conditions like sepsis, a delay of even a few hours can be fatal. Yet for many other conditions, too, the ability to get fast, accurate, multi-dimensional results at the point of care is key to better treatment and improved outcomes.

*https://www.nature.com/articles/ncomms5212

7 reasons

The Solution

Attomarker is transforming diagnostics with its ground breaking biomarker technology, delivering lab-quality results in just 7–10 minutes. By measuring multiple biomarkers from a single finger prick of blood, our technology enables a more personalised, data-driven approach to healthcare.

Our unique gold nanoparticle technology provides fully quantitative results, ensuring higher accuracy than traditional rapid tests. With AI-driven analysis, Attomarker’s platform can detect patterns across multiple biomarkers, offering a deeper understanding of disease progression.

How Attomarker is Changing Diagnostics:

  • Faster Diagnosis & Treatment – Results in minutes, ensuring clinicians can act immediately.
  • Comprehensive Testing – Multi-biomarker analysis for a detailed health profile, covering infections, fertility, liver health, and chronic diseases.
  • AI-Powered Precision – Enhances diagnostic accuracy, reducing misdiagnosis and unnecessary treatments.
  • Point-of-Care Accessibility – Testing can be done in clinics, pharmacies, workplaces, and even at home, removing the reliance on central labs.
  • Cost-Effective & Scalable – Reduces the need for multiple hospital visits, saving time and healthcare costs.

Attomarker is setting a new global standard for rapid, personalised diagnostics, ensuring that healthcare professionals have the right information, at the right time, to deliver better patient care.

The Company

Attomarker is a British company, founded in 2008 as a spin-out from Professor Andrew Shaw’s research group at the University of Exeter. Our award-winning nanophotonic technology enables fast, reliable, and personalised diagnostics, revolutionising the way diseases are detected and managed.

We believe that new health challenges demand innovative solutions, and we are dedicated to delivering gold-standard, rapid tests that empower clinicians and patients alike. Our mission is to make high-quality diagnostics accessible to all, bridging the gap between laboratory precision and real-world healthcare needs.